Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-004628
Filing Date
2025-01-21
Accepted
2025-01-21 06:01:07
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 4727
  Complete submission text file 0001104659-25-004628.txt   6454
Mailing Address 12750 HIGH BLUFF DRIVE SUITE 475 SAN DIEGO CA 92130
Business Address 12750 HIGH BLUFF DRIVE SUITE 475 SAN DIEGO CA 92130 858-246-6240
BELITE BIO, INC (Subject) CIK: 0001889109 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93970 | Film No.: 25540235
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 36F., NO. 68, SEC. 5, ZHONGXIAO E. RD., XINYI DISTRICT TAIPEI CITY F5 110
Business Address 36F., NO. 68, SEC. 5, ZHONGXIAO E. RD., XINYI DISTRICT TAIPEI CITY F5 110 886287805008
Lin Bioscience International Ltd. (Filed by) CIK: 0001965750 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G